“O.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaClosed”
Netpaintings from leading pharmaceutical centers brings unmatched scalability, flexibility and expertise to the global response
WALTHAM, Mass., July 20, 2020 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects globally.
“Long before the pandemic, we were the best strategic friend by investing in captalents and captalents to continue with the best friend and the flexibility of the source chain for our clients, allowing us to pivot temporarily to help the COVID-1 reaction as well,” Marc N said. Casper, president, president and CEO of Thermo Fisher Scientific. “The combined apple is well placed to take the initiative to assist in the design of COVID-1 vaccines and therapies in addition to providing essential medicines to patients for the treatment of cancer, genetic diseases and other serious health problems.”
To accelerate vaccine progression in the United States, the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for the Preparation and Response of Health Services Decomposition and Huguy, announced investments to help expand Thermo Fisher Capatown production for sterile injectables, which is also used to fill a h8 volume of vaccine doses. Thermo Fisher also helps several global vaccine systems that are or are entering huguy clinical trials, providing critical capacity and experience that delights in accelerated progression and preparation over the months.
The combined apple has also expanded the capacity of consumers who are preparing new and existing therapies, adding promising antiviral drugs, to meet design demand and allow biopharmaceutical consumers to reduce delivery times to patients. For example, through the accelerated manufacture of uncommon anti-inflammatory therapy to alleviate coVID-19 symptoms, the Thermo Fisher group station produced and distributed a year of medication in just over a month, helping to satisfy a design in the hospital call for.
In addition to its vaccine paints and remedies applicable to COVID-19, the continuous apple continues so that patients undergoing clinical trials continue to obtain the essential medicines they need. A “site-to-patient” program, announced at the birth of the pandemic, provided clinical trial patients with uninterrupted access to life-saving experimental intellectual drug shipments without the need to move to a clinic, one of the efforts to maintain the continuity of the chain of origin. The pandemic. .
Learn more about Thermo Fisher Pharma and its reaction to COVID-1nine here.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world’s leading scientific company, with annual sales of more than $2 billion. Our task is to enable our consumers to make the world healthier, cleaner and safer. Whether our clients are life science research experts, solve complex analytical challenges, get better diagnostics and therapies for patients, or expand productivity in their labs, we’re at your disposal. Our global team of over 7,5,000 colleagues delivers an unprecedented mix of cutting-edge technologies, convenience and pharmaceutical centers across our industry-leading brands, adding Thermo Scientific, Applied Biosystems, Invitrogen, Scientific Fisher, Unity Lab Services and Patheon. For more information, visit www.thermofisher.com.
Media Contact: Ron O’Brien Phone: 781-622-12 Email: [email protected]
Investor Contact: Ken Apicerno Phone: 781-622-12 Email: [email protected]
See the content to download the media: http://www.prnewswire.com/news-releases/thermo-fisher-scientifics-response-to-covid-19-continues-to-expand-to-support-development-and-production-of-therapeutic-and-vaccines-301095565.html
SOURCE Thermo Fisher Scientific